Simultaneous RP-HPLC determination of abacavir, lamivudine and dolutegravir in bulk API dosage forms


  • M.Monica
  • D.Gowri Sankar


RP-HPLC, Abacavir, Lamivudine, Dolutegravir, combination


The RP-HPLC method was developed and validated for the determination of a combination of Abacavir, Lamivudine and
Dolutegravir in bulk API forms. The chromatography was carried out on Agilent C18 column (100mm x 4.6mm, 3.5µ)
using a mobile phase of Ammonium formate and methanol in the ratio of 40:60, at a flow rate of 0.8ml/minute. The
analytes were monitored at 262nm using a PDA detector. The retention time of Abacavir, Lamivudine and Dolutegravir
were observed at 1.73, 1.30 and 4.32 minutes respectively. The developed method was found to be linear in the
concentration range of 5µg-50µg having r2
value of 0.999, 0.999 and 0.998 for Abacavir, Lamivudine and Dolutegravir
respectively. The method has been validated according to ICH guidelines.